IS6803A - GABA eflar í meðhöndlun á sjúkdómum sem varða minnkaða taugasteróíð virkni - Google Patents

GABA eflar í meðhöndlun á sjúkdómum sem varða minnkaða taugasteróíð virkni

Info

Publication number
IS6803A
IS6803A IS6803A IS6803A IS6803A IS 6803 A IS6803 A IS 6803A IS 6803 A IS6803 A IS 6803A IS 6803 A IS6803 A IS 6803A IS 6803 A IS6803 A IS 6803A
Authority
IS
Iceland
Prior art keywords
management
diseases related
steroid activity
decreased neuronal
gaba
Prior art date
Application number
IS6803A
Other languages
English (en)
Other versions
IS2427B (is
Inventor
Ebert Bjarke
Høngaard Andersen Peter
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8159857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS6803(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of IS6803A publication Critical patent/IS6803A/is
Publication of IS2427B publication Critical patent/IS2427B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS6803A 2000-11-20 2003-04-30 Notkun á gaboxadóli til meðhöndlunar á fyrirtíðatruflun, eftirburðarþunglyndi eða eftirtíðatengdri vanlíðan IS2427B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200001743 2000-11-20
PCT/DK2001/000773 WO2002040009A1 (en) 2000-11-20 2001-11-20 Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity

Publications (2)

Publication Number Publication Date
IS6803A true IS6803A (is) 2003-04-30
IS2427B IS2427B (is) 2008-10-15

Family

ID=8159857

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6803A IS2427B (is) 2000-11-20 2003-04-30 Notkun á gaboxadóli til meðhöndlunar á fyrirtíðatruflun, eftirburðarþunglyndi eða eftirtíðatengdri vanlíðan

Country Status (33)

Country Link
US (2) US20040024038A1 (is)
EP (1) EP1337247B1 (is)
JP (1) JP4152186B2 (is)
KR (1) KR100865651B1 (is)
CN (1) CN1318027C (is)
AR (1) AR031473A1 (is)
AT (1) ATE336242T1 (is)
AU (2) AU2351402A (is)
BG (1) BG107909A (is)
BR (1) BR0115668A (is)
CA (1) CA2429220C (is)
CY (1) CY1106209T1 (is)
CZ (1) CZ20031383A3 (is)
DE (1) DE60122368T2 (is)
DK (1) DK1337247T3 (is)
EA (1) EA007287B1 (is)
ES (1) ES2266308T3 (is)
HR (1) HRP20030404A2 (is)
HU (1) HUP0400505A3 (is)
IL (1) IL155587A0 (is)
IS (1) IS2427B (is)
ME (1) MEP6408A (is)
MX (1) MXPA03004349A (is)
NO (1) NO20032271L (is)
NZ (1) NZ525520A (is)
PL (1) PL361051A1 (is)
PT (1) PT1337247E (is)
SI (1) SI1337247T1 (is)
SK (1) SK7682003A3 (is)
UA (1) UA77403C2 (is)
WO (1) WO2002040009A1 (is)
YU (1) YU39003A (is)
ZA (1) ZA200303289B (is)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2003045411A2 (de) * 2001-11-26 2003-06-05 Finzelberg Gmbh & Co. Kg Ingwer-extraktzubereitung
EP1641456B1 (en) * 2003-06-25 2010-03-03 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
EP1761263A1 (en) * 2004-06-29 2007-03-14 H. Lundbeck A/S Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis
WO2006012563A2 (en) * 2004-07-23 2006-02-02 The Regents Of The University Of California Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
US8022084B2 (en) 2005-01-28 2011-09-20 H. Lundbeck A/S Polymorphic forms of a GABAA agonist
US20070122507A1 (en) * 2005-05-26 2007-05-31 Palu Afa K Histone deacetylase and tumor necrosis factor converting enzyme inhibition
US8280978B2 (en) * 2006-12-29 2012-10-02 Prodea Systems, Inc. Demarcation between service provider and user in multi-services gateway device at user premises
WO2008141112A1 (en) * 2007-05-09 2008-11-20 Cenerx Biopharma, Inc. Methods of treating rett syndrome
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
WO2012173634A1 (en) * 2011-06-16 2012-12-20 Solace Lifesciences, Inc. Systems and methods for balancing and maintaining the health of the human autonomic nervous system
RU2496496C1 (ru) * 2012-10-04 2013-10-27 Исаак Григорьевич Гитлин Фармацевтическая композиция, обладающая гамк-ергической активностью
IL256912B2 (en) 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods of treating developmental disorders with gaboxadol
WO2018031748A1 (en) * 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
KR102049522B1 (ko) * 2018-06-05 2019-11-27 충남대학교산학협력단 Gaba를 유효성분으로 하는 살모넬라 감염질환의 예방 및 치료용 조성물
KR102049526B1 (ko) * 2018-06-05 2019-11-27 충남대학교산학협력단 Gaba를 유효성분으로 하는 항결핵 약학 조성물
WO2020061410A1 (en) 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
GB2594616A (en) 2018-11-21 2021-11-03 Certego Therapeutics Inc Gaboxadol for reducing risk of suicide and rapid relief of depression
CN113423399A (zh) 2018-12-17 2021-09-21 奥维德医疗公司 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
CN114786669A (zh) 2019-12-18 2022-07-22 奥维德医疗公司 用于1p36缺失综合征的治疗性治疗的加波沙朵
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
CN114404437A (zh) * 2022-03-15 2022-04-29 山东中医药大学 没食子酰芍药苷在制备gabaa受体抑制剂中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362731A (en) * 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
EP0603312A4 (en) * 1991-09-13 1995-06-07 Cocensys Inc NEW GABA A RECEPTOR WITH STEROID BINDING POINTS.
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
CZ300694A3 (en) * 1993-12-02 1996-05-15 Akzo Nobel Nv Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
WO1996016076A1 (en) * 1994-11-23 1996-05-30 Cocensys, Inc. Androstane and pregnane series for allosteric modulation of gaba receptor
US5776959A (en) * 1995-06-05 1998-07-07 Washington University Anticonvulsant and anxiolytic lactam and thiolactam derivatives
KR19990022323A (ko) * 1995-06-06 1999-03-25 씨. 랜 낸시 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드
IT1290003B1 (it) * 1997-03-03 1998-10-19 Angelini Ricerche Spa Uso di pivagabina per preparare composizioni farmaceutiche
GB9801208D0 (en) * 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
KR100599142B1 (ko) * 1998-07-22 2006-07-12 악조 노벨 엔.브이. α- 아미노산 페닐 에스테르 유도체
MXPA02004829A (es) * 1999-12-08 2003-10-14 Warner Lambert Co Metodo para la sintesis estereoselectiva de aminoacidos ciclicos.

Also Published As

Publication number Publication date
CZ20031383A3 (cs) 2003-08-13
DE60122368D1 (de) 2006-09-28
EA007287B1 (ru) 2006-08-25
SI1337247T1 (sl) 2006-12-31
DK1337247T3 (da) 2006-12-04
IL155587A0 (en) 2003-11-23
IS2427B (is) 2008-10-15
ATE336242T1 (de) 2006-09-15
ZA200303289B (en) 2005-07-27
CA2429220C (en) 2009-09-15
BG107909A (bg) 2004-08-31
US20040024038A1 (en) 2004-02-05
SK7682003A3 (en) 2003-10-07
NZ525520A (en) 2005-04-29
CY1106209T1 (el) 2011-06-08
EP1337247B1 (en) 2006-08-16
AR031473A1 (es) 2003-09-24
WO2002040009A1 (en) 2002-05-23
CA2429220A1 (en) 2002-05-23
AU2002223514B2 (en) 2006-11-30
HUP0400505A2 (hu) 2004-07-28
CN1318027C (zh) 2007-05-30
KR100865651B1 (ko) 2008-10-29
MEP6408A (xx) 2010-02-10
US20090143435A1 (en) 2009-06-04
DE60122368T2 (de) 2007-08-09
JP4152186B2 (ja) 2008-09-17
AU2351402A (en) 2002-05-27
BR0115668A (pt) 2003-09-02
CN1592616A (zh) 2005-03-09
MXPA03004349A (es) 2003-08-19
EA200300594A1 (ru) 2003-10-30
KR20030065517A (ko) 2003-08-06
UA77403C2 (en) 2006-12-15
YU39003A (sh) 2006-05-25
HK1075010A1 (en) 2005-12-02
PT1337247E (pt) 2006-11-30
HUP0400505A3 (en) 2008-08-28
ES2266308T3 (es) 2007-03-01
HRP20030404A2 (en) 2005-04-30
EP1337247A1 (en) 2003-08-27
PL361051A1 (en) 2004-09-20
JP2004513921A (ja) 2004-05-13
NO20032271D0 (no) 2003-05-20
NO20032271L (no) 2003-05-20

Similar Documents

Publication Publication Date Title
IS6803A (is) GABA eflar í meðhöndlun á sjúkdómum sem varða minnkaða taugasteróíð virkni
NO20031442D0 (no) Morfolin-acetamidderivater for behandling av inflammatoriske sykdommer
IS8233A (is) Própíónsýruafleiður sem eru gagnlegar í meðhöndlun á fitusjúkdómum
IS7814A (is) Fenetanólamín afleiða í meðhöndlun á öndunarfærasjúkdómum.
IL155092A0 (en) Compounds useful in the treatment of inflammatory diseases
IL163725A0 (en) Administration of agents for the treatment of inflammation
NO20026008L (no) Fremgangsmåte for behandling av cardiovaskul¶re sykdommer
DE60031710D1 (de) Fettsäurederivat zur behandlung von externen sekretionsstörungen
PL374118A1 (en) Interleukin-1 receptors in the treatment of diseases
GB0113502D0 (en) A method of incentivising members of a disease management programme to comply with the programme
IS7456A (is) Fosfat forlyf flúoróoxindóla
ID26441A (id) Proses untuk memproduksi ftalat anhidrida
IS7528A (is) Nýir etónógestrel esterar
IS7444A (is) Morfólínýl-þvagefna afleiður til notkunar við meðhöndlun á bólguvaldandi sjúkdómum
ID26478A (id) Penggambaran kelima macam langkah produksi
ID26097A (id) Proses pembuatan pakaian luar sekali pakai
FI20020593A0 (fi) Menetelmä konjugoidun linolihapon valmistamiseksi
DK1309322T3 (da) Anvendelse af 3-benzoylphenyleddikesyrederivater til behandling af retinale lidelser
NO20014081D0 (no) Anvendelse av tianeptin i produksjonen av medikamenter til behandling av nevrodegenerative patologier
ID24405A (id) Pembnalut kesehatan yang dilengkapi dengan sayap
ITMI20001216A0 (it) Impiego dell'aloe-emodin nel trattamento di patologie neoplastiche diorigine neuroectodermica
NO20022001D0 (no) 6-metoksy-2-naftyleddiksyre-prodroger til behandling av inflammasjon
IS7868A (is) Notkun á kortkólíberín-úrókortín kerfi í meðferð á bólguvaldandi sjúkdómum.
ZA200409498B (en) Use of new etonogestrel esters
AU2003208776A1 (en) Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases